Skip to main content
Top
Published in: BMC Infectious Diseases 1/2008

Open Access 01-12-2008 | Research article

Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study

Authors: Katherine L Fielding, Salome Charalambous, Amy L Stenson, Lindiwe F Pemba, Des J Martin, Robin Wood, Gavin J Churchyard, Alison D Grant

Published in: BMC Infectious Diseases | Issue 1/2008

Login to get access

Abstract

Background

Reasons for the variation in reported treatment outcomes from antiretroviral therapy (ART) programmes in developing countries are not clearly defined.

Methods

Among ART-naïve individuals in a workplace ART programme in South Africa we determined virological outcomes at 12 months, and risk factors for suboptimal virological outcome, defined as plasma HIV-1 viral load >= 400 copies/ml.

Results

Among 1760 individuals starting ART before July 2004, 1172 were in follow-up at 12 months of whom 953 (81%) had a viral load measurement (median age 41 yrs, 96% male, median baseline CD4 count 156 × 106/l). 71% (681/953) had viral load < 400 copies/ml at 12 months. In a multivariable analysis, independent predictors of suboptimal virological outcome at 12 months were <1 log decrease in viral load at six weeks (odds ratio [OR] 4.71, 95% confidence interval [CI] 2.56–8.68), viral load at baseline (OR 3.63 [95% CI 1.88–7.00] and OR 3.54 [95% CI 1.79–7.00] for 10,001–100,000 and >100,000 compared to <= 10,000 copies/ml, respectively), adherence at six weeks (OR 3.50 [95% CI 1.92–6.35]), WHO stage (OR 2.08 [95% CI 1.28–3.34] and OR 2.03 [95% CI 1.14–3.62] for stage 3 and 4 compared to stage 1–2, respectively) and site of ART delivery. Site of delivery remained an independent risk factor even after adjustment for individual level factors. At 6 weeks, of 719 patients with self-reported adherence and viral load, 72 (10%) reported 100% adherence but had <1 log decrease in viral load; conversely, 60 (8%) reported <100% adherence but had >= 1 log decrease in viral load.

Conclusion

Virological response at six weeks after ART start was the strongest predictor of suboptimal virological outcome at 12 months, and may identify individuals who need interventions such as additional adherence support. Self reported adherence was less strongly associated but identified different patients compared with viral load at 6 weeks. Site of delivery had an important influence on virological outcomes; factors at the health system level which influence outcome need further investigation to guide development of effective ART programmes.
Appendix
Available only for authorised users
Literature
3.
go back to reference Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000, 133: 21-30.CrossRefPubMed Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N: Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000, 133: 21-30.CrossRefPubMed
4.
go back to reference Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997, 277: 1962-1969. 10.1001/jama.277.24.1962.CrossRefPubMed Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997, 277: 1962-1969. 10.1001/jama.277.24.1962.CrossRefPubMed
5.
go back to reference García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Deficiency. 2002, 30: 105-110. 10.1097/00126334-200205010-00014.CrossRef García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA: Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Deficiency. 2002, 30: 105-110. 10.1097/00126334-200205010-00014.CrossRef
6.
go back to reference Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO: Predicting the unpredictable: Transmission of drug resistant HIV. Nat Med. 2001, 7: 1016-1020. 10.1038/nm0901-1016.CrossRefPubMed Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO: Predicting the unpredictable: Transmission of drug resistant HIV. Nat Med. 2001, 7: 1016-1020. 10.1038/nm0901-1016.CrossRefPubMed
7.
go back to reference Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E: Outcomes after two years of providing ART in Khayelitsha, South Africa. AIDS. 2004, 18: 887-895. 10.1097/00002030-200404090-00006.CrossRefPubMed Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, Labatala V, Reuter H, Ntwana N, Goemaere E: Outcomes after two years of providing ART in Khayelitsha, South Africa. AIDS. 2004, 18: 887-895. 10.1097/00002030-200404090-00006.CrossRefPubMed
8.
go back to reference Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright PF, Gulick R, Johnson WD, Pape JW, Fitzgerald DW: Antiretroviral therapy in a thousand patients with AIDS in Haiti. NEJM. 2005, 353: 2325-34. 10.1056/NEJMoa051908.CrossRefPubMed Severe P, Leger P, Charles M, Noel F, Bonhomme G, Bois G, George E, Kenel-Pierre S, Wright PF, Gulick R, Johnson WD, Pape JW, Fitzgerald DW: Antiretroviral therapy in a thousand patients with AIDS in Haiti. NEJM. 2005, 353: 2325-34. 10.1056/NEJMoa051908.CrossRefPubMed
9.
go back to reference Bekker LG, Myer L, Orrell C, Lawn S, Wood R: Rapid scale-up of community-based HIV treatment service. Programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006, 96 (4): 315-320.PubMed Bekker LG, Myer L, Orrell C, Lawn S, Wood R: Rapid scale-up of community-based HIV treatment service. Programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J. 2006, 96 (4): 315-320.PubMed
10.
go back to reference Laurent C, Diakhaté N, Gueye NF, Touré MA, Sow PS, Faye MA, Gueye M, Lanièce I, Touré Kane C, Liégeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E: The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002, 16: 1363-70. 10.1097/00002030-200207050-00008.CrossRefPubMed Laurent C, Diakhaté N, Gueye NF, Touré MA, Sow PS, Faye MA, Gueye M, Lanièce I, Touré Kane C, Liégeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E: The Senegalese government's highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002, 16: 1363-70. 10.1097/00002030-200207050-00008.CrossRefPubMed
11.
go back to reference Macharia DK, Chang LW, Lule G, Owili DM, Tesfaledet G, Patel S, Silverstein DM, Ng'ang'a L, Bush T, De Cock KM, Weidle PJ: Antiretroviral therapy in the private sector of Nairobi, Kenya: a review of the experience of five physicians. AIDS. 2003, 17: 938-940. 10.1097/00002030-200304110-00028.CrossRefPubMed Macharia DK, Chang LW, Lule G, Owili DM, Tesfaledet G, Patel S, Silverstein DM, Ng'ang'a L, Bush T, De Cock KM, Weidle PJ: Antiretroviral therapy in the private sector of Nairobi, Kenya: a review of the experience of five physicians. AIDS. 2003, 17: 938-940. 10.1097/00002030-200304110-00028.CrossRefPubMed
12.
go back to reference Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, Maurice C, Nkengasong J, Konan-Koko R, Kadio A, Wiktor S, Lackritz E, Saba J, Chorba T: Virological and immunological outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS. 2003, 17 (suppl 3): S5-15.CrossRefPubMed Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, Maurice C, Nkengasong J, Konan-Koko R, Kadio A, Wiktor S, Lackritz E, Saba J, Chorba T: Virological and immunological outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Côte d'Ivoire. AIDS. 2003, 17 (suppl 3): S5-15.CrossRefPubMed
13.
go back to reference Hofer CB, Schechter M, Harrison LH: Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2004, 36: 967-71. 10.1097/00126334-200408010-00011.CrossRefPubMed Hofer CB, Schechter M, Harrison LH: Effectiveness of antiretroviral therapy among patients who attend public HIV clinics in Rio de Janeiro, Brazil. J Acquir Immune Defic Syndr. 2004, 36: 967-71. 10.1097/00126334-200408010-00011.CrossRefPubMed
14.
go back to reference Knobel H, Guelar A, Carmona A, Espona M, González A, López-Colomés JL, Saballs P, Gimeno JL, Díez A: Virological outcomes and predictors of virological failure of active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDs. 2001, 15: 193-9. 10.1089/10872910151133729.CrossRefPubMed Knobel H, Guelar A, Carmona A, Espona M, González A, López-Colomés JL, Saballs P, Gimeno JL, Díez A: Virological outcomes and predictors of virological failure of active antiretroviral therapy containing protease inhibitors. AIDS Patient Care STDs. 2001, 15: 193-9. 10.1089/10872910151133729.CrossRefPubMed
15.
go back to reference Kitchen CM, Kitchen SG, Dubin JA, Gottlieb MS: Initial virological and immunological response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin Infect Dis. 2001, 33: 466-472. 10.1086/321900.CrossRefPubMed Kitchen CM, Kitchen SG, Dubin JA, Gottlieb MS: Initial virological and immunological response to highly active antiretroviral therapy predicts long-term clinical outcome. Clin Infect Dis. 2001, 33: 466-472. 10.1086/321900.CrossRefPubMed
16.
go back to reference Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ: Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999, 13: 1873-1880. 10.1097/00002030-199910010-00009.CrossRefPubMed Powderly WG, Saag MS, Chapman S, Yu G, Quart B, Clendeninn NJ: Predictors of optimal virological response to potent antiretroviral therapy. AIDS. 1999, 13: 1873-1880. 10.1097/00002030-199910010-00009.CrossRefPubMed
17.
go back to reference Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B, Swiss HIV Cohort Study; Frakfurt HIV Clinic Cohort; EuroSIDA Study Group: HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001, 286: 2560-7. 10.1001/jama.286.20.2560.CrossRefPubMed Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B, Swiss HIV Cohort Study; Frakfurt HIV Clinic Cohort; EuroSIDA Study Group: HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. JAMA. 2001, 286: 2560-7. 10.1001/jama.286.20.2560.CrossRefPubMed
18.
go back to reference Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F: Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 2001, 15: 1369-1377. 10.1097/00002030-200107270-00006.CrossRefPubMed Bartlett JA, DeMasi R, Quinn J, Moxham C, Rousseau F: Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 2001, 15: 1369-1377. 10.1097/00002030-200107270-00006.CrossRefPubMed
19.
go back to reference Charalambous S, Grant AD, Day JH, Pemba L, Chaisson RE, Kruger P, Martin D, Wood R, Brink B, Churchyard GJ: Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care. 2007, 19: 34-41. 10.1080/09500340600677872.CrossRefPubMed Charalambous S, Grant AD, Day JH, Pemba L, Chaisson RE, Kruger P, Martin D, Wood R, Brink B, Churchyard GJ: Establishing a workplace antiretroviral therapy programme in South Africa. AIDS Care. 2007, 19: 34-41. 10.1080/09500340600677872.CrossRefPubMed
20.
go back to reference WHO: Interim proposal for a WHO staging system for HIV infection and disease. Weekly Epidemiological Record. 1990, 65: 221-224. WHO: Interim proposal for a WHO staging system for HIV infection and disease. Weekly Epidemiological Record. 1990, 65: 221-224.
21.
go back to reference Coetzee D, Boulle A, Hildebrand K, Asselman V, Van Cutsem G, Goemaere E: Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS. 2004, 18 (suppl 3): S27-S31. 10.1097/00002030-200406003-00006.CrossRefPubMed Coetzee D, Boulle A, Hildebrand K, Asselman V, Van Cutsem G, Goemaere E: Promoting adherence to antiretroviral therapy: the experience from a primary care setting in Khayelitsha, South Africa. AIDS. 2004, 18 (suppl 3): S27-S31. 10.1097/00002030-200406003-00006.CrossRefPubMed
22.
go back to reference The Antiretroviral Therapy in Lower Income Countries (ART-LINC) and ART Cohort Collaboration (ART-CC) groups: Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006, 367: 817-824. 10.1016/S0140-6736(06)68337-2.CrossRef The Antiretroviral Therapy in Lower Income Countries (ART-LINC) and ART Cohort Collaboration (ART-CC) groups: Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006, 367: 817-824. 10.1016/S0140-6736(06)68337-2.CrossRef
23.
go back to reference Lawn SD, Myer L, Orrell C, Bekker LG, Wood R: Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005, 19: 2141-2148.CrossRefPubMed Lawn SD, Myer L, Orrell C, Bekker LG, Wood R: Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005, 19: 2141-2148.CrossRefPubMed
24.
go back to reference Moore RD, Keruly JC, Gebo KA, Lucas GM: An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr. 2005, 39: 195-198.PubMed Moore RD, Keruly JC, Gebo KA, Lucas GM: An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr. 2005, 39: 195-198.PubMed
25.
go back to reference Charalambous S, Innes C, Muirhead D, Kumaranayake L, Fielding K, Pemba L, Hamilton R, Grant A, Churchyard GJ: Evaluation of a workplace HIV treatment programme in South Africa. AIDS. 2007, 21 (suppl 3): S73-S78. 10.1097/01.aids.0000279696.63438.aa.CrossRefPubMed Charalambous S, Innes C, Muirhead D, Kumaranayake L, Fielding K, Pemba L, Hamilton R, Grant A, Churchyard GJ: Evaluation of a workplace HIV treatment programme in South Africa. AIDS. 2007, 21 (suppl 3): S73-S78. 10.1097/01.aids.0000279696.63438.aa.CrossRefPubMed
26.
go back to reference Rosen S, Fox MP, Gill CJ: Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007, 4 (10): e298-10.1371/journal.pmed.0040298.CrossRefPubMedPubMedCentral Rosen S, Fox MP, Gill CJ: Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med. 2007, 4 (10): e298-10.1371/journal.pmed.0040298.CrossRefPubMedPubMedCentral
27.
go back to reference Lepri AC, Miller V, Phillips AN, Rabenau H, Sabin CA, Staszewski S: The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral load. AIDS. 2001, 15: 47-54. 10.1097/00002030-200101050-00008.CrossRefPubMed Lepri AC, Miller V, Phillips AN, Rabenau H, Sabin CA, Staszewski S: The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4–8 viral load. AIDS. 2001, 15: 47-54. 10.1097/00002030-200101050-00008.CrossRefPubMed
28.
go back to reference Smith CJ, Staszewski S, Sabin CA, Nelson M, Dauer B, Gute P, Johnson MA, Phillips AN, Gazzard B: Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr. 2004, 37: 1155-1159. 10.1097/01.qai.0000135958.80919.e4.CrossRefPubMed Smith CJ, Staszewski S, Sabin CA, Nelson M, Dauer B, Gute P, Johnson MA, Phillips AN, Gazzard B: Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals. J Acquir Immune Defic Syndr. 2004, 37: 1155-1159. 10.1097/01.qai.0000135958.80919.e4.CrossRefPubMed
Metadata
Title
Risk factors for poor virological outcome at 12 months in a workplace-based antiretroviral therapy programme in South Africa: A cohort study
Authors
Katherine L Fielding
Salome Charalambous
Amy L Stenson
Lindiwe F Pemba
Des J Martin
Robin Wood
Gavin J Churchyard
Alison D Grant
Publication date
01-12-2008
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2008
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-8-93

Other articles of this Issue 1/2008

BMC Infectious Diseases 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.